# Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma

> **NCT04248387** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Melanoma Stage IIIB-IV

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04248387
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-17
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248387, "Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04248387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*